Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DGAT2 | Q96PD7 | 1/20 | 0.37 |
| ▸ | WNT3A | P56704 | 1/20 | 0.37 |
| ▸ | GRM1 | Q13255 | 7/20 | 0.36 |
| ▸ | GRM5 | P41594 | 6/20 | 0.36 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.36 |
| ▸ | EED | O75530 | 1/20 | 0.35 |
| ▸ | RBBP4 | Q09028 | 1/20 | 0.35 |
| ▸ | SUZ12 | Q15022 | 1/20 | 0.35 |
| ▸ | EZH2 | Q15910 | 1/20 | 0.35 |
| ▸ | TNK2 | Q07912 | 1/20 | 0.35 |
| ▸ | CDK9 | P50750 | 2/20 | 0.35 |
| ▸ | CNR1 | P21554 | 1/20 | 0.35 |
| ▸ | PDK4 | Q16654 | 1/20 | 0.34 |
| ▸ | NAMPT | P43490 | 1/20 | 0.34 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17535146 | 0.84 | CDK9 (0.47) | CDK9 | |
| SCHEMBL17837491 | 0.80 | GRM1 (0.41) | DGAT2WNT3AGRM1GRM5EED | |
| SCHEMBL16052625 | 0.75 | NPC1 (0.35) | — | |
| SCHEMBL17837729 | 0.75 | GRM1 (0.44) | WNT3AGRM1GRM5EEDRBBP4 | |
| SCHEMBL17704152 | 0.74 | CDK9 (0.48) | WNT3AGRM1GRM5EEDRBBP4 | |
| SCHEMBL23294320 | 0.73 | GRM1 (0.44) | WNT3AGRM1GRM5ADORA1TNK2 | |
| SCHEMBL17837904 | 0.72 | GRM1 (0.42) | WNT3AGRM1GRM5EEDRBBP4 | |
| SCHEMBL16052395 | 0.72 | CDK9 (0.55) | CDK9 | |
| SCHEMBL16051630 | 0.71 | MAPT (0.41) | — | |
| SCHEMBL12874666 | 0.70 | GRM1 (0.49) | DGAT2GRM1GRM5EEDRBBP4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9796708-B2 | Pyrrolo [2,3-B] pyridine CDK9 kinase inhibitors | ABBVIE INC. (US) | 2017-10-24 | — | — | US | disclosed |
| US-20160060257-A1 | PYRROLO [2,3-B] PYRIDINE CDK9 KINASE INHIBITORS | ABBVIE INC. (US) | 2016-03-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160060257-A1 | PYRROLO [2,3-B] PYRIDINE CDK9 KINASE INHIBITORS | CDK9, CDK19, CDK3 | DGAT2 4827/4885WNT3A 2217/4885GRM1 2475/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.